logo

닫기 버튼

logo

닫기 버튼
Selective Regulation of Signal Pathway

SSR™ : Signal-path Selective Regulation

Selectively targets only highly specific and pathological signals

Minimizes toxicity and side effects due to a short half-life in the bloodstream

Selective Regulation of TGF-β Smad Signals

P2K: Selective Modulation of TGF-β Smad1/5/9 & Smad2/3

E1K: Precise Inhibition of TGF-β Smad1/5/9 alone

C1K: Precise Inhibition of TGF-β Smad2/3 alone

ESAIDD™ AI-Driven Drug Discovery System

Accelerating the discovery of high-probability drug candidates

Powered by LLMs and Machine Learning Demonstrating ESAIDD’s Reliability through the Discovery of D1K, a Trop-2–Targeting Peptide

New Drugs for Unmet Needs

P2K – A Novel Therapy for Degenerative Disc Disease (DDD)

E1K – A Novel Therapy for Knee Osteoarthritis (OA)

M1K – A Novel Therapy for Alzheimer’s Disease (AD)

NOTICE & NEWS

Notice

+ More
2026-07-21
2026-01-23
2026-01-02
2025-12-24

Ensol News

+ More
2026-08-04
2026-07-07
2026-07-01
2026-06-29

CLINICAL STAGE PIPELINE

Pipeline Indication Pre-Clinical Phase1 Phase2 Phase1 NDA or L/O
P2KPeniel2000

Degenerative Disc Disease
SB Logo

Expanding indications
SB Logo
E1KEngedi1000

Human Osteoarthritis

Animal Osteoarthritis
C1KCharis1000

TNBC
C2KCharis2000

NSCLC
Pipeline
P2K브니엘2000
적응증
퇴행성디스크질환
진행현황
상세보기 →
Pipeline
P2K브니엘2000
적응증
적응증 확대
진행현황
상세보기 →
Pipeline
E1K엔게디1000
적응증
인간 골관절염
진행현황
상세보기 →
Pipeline
E1K엔게디1000
적응증
동물 골관절염
진행현황
상세보기 →
Pipeline
C1K카리스1000
적응증
삼중음성유방암(TNBC)
진행현황
상세보기 →
Pipeline
C2K카리스2000
적응증
비소세포폐암(NSCLC)
진행현황
상세보기 →
▶ ENSOL PIPELINE DETAILS

E1K: Breakthrough to become the world's first DMOAD

TECHNOLOGY

1. ESAIDD - AI-Driven Cyclic Peptide Drug Candidate Discovery

2. ETONS - AI-based MoA Prediction System

FIRST-IN-CLASS DRUGS

1. P2K - Degenerative Disc Disease (DDD) Therapy

2. E1K - Osteoarthritis (OA) Therapy

3. C1K - Anticancer Drugs

4. D1K - PDC Peptide targeting Trop-2

5. M1K - Therapeutics targeting for the Early-Stage Alzheimer's Disease

6. H1K - Oral Anti-Obesity Medication